Larimar Therapeutics, Inc.
LRMR
$2.97
$0.113.85%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -111.26% | -118.15% | -94.04% | -78.75% | -36.85% |
| Total Depreciation and Amortization | 4.15% | 2.25% | 4.55% | 4.85% | -0.32% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -52.19% | -41.11% | -35.63% | -21.01% | 11.88% |
| Change in Net Operating Assets | 110.47% | 345.92% | 188.93% | 1,382.42% | 852.62% |
| Cash from Operations | -139.24% | -111.48% | -89.32% | -56.35% | -31.65% |
| Capital Expenditure | -243.90% | -214.02% | -- | -- | -64.00% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 98.42% | -353.22% | -556.61% | -773.57% | -9,243.67% |
| Cash from Investing | 97.98% | -356.01% | -559.69% | -775.21% | -9,965.19% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -99.96% | 540,623.33% | 540,503.33% | 114.60% | 114.60% |
| Repurchase of Common Stock | -- | -- | -5.70% | -5.70% | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -100.17% | 539,510.00% | 56,689.86% | 115.06% | 115.50% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -6,314.01% | 7,647.37% | 92.28% | -183.14% | -102.86% |